Arcutis Biotherapeutics Hits New 52-Week High of $19.36

Arcutis Biotherapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 19.36 on September 30, 2025. This achievement underscores the company's impressive performance over the past year, with a remarkable 150% increase compared to the S&P 500's 16.09% gain during the same period.
The company's market capitalization stands at USD 2,080 million, reflecting its position within the small-cap category. Despite being loss-making, Arcutis has demonstrated strong growth metrics, including a 164.13% increase in net sales and positive results for the last seven consecutive quarters. The stock's performance has been bolstered by high institutional holdings at 100%, indicating robust confidence from sophisticated investors.

Additionally, the stock's operating cash flow has reached its highest at USD -65.5 million, while the return on capital employed (ROCE) for the first half of the year is at -57.33%. With a price-to-book ratio of 14.97 and a 52-week low of USD 8.03, Arcutis Biotherapeutics continues to capture attention in the market.